Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 3
2021 5
2022 2
2023 4
2024 6
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Kantarjian H, et al. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. N Engl J Med. 2017. PMID: 28249141 Free PMC article. Clinical Trial.
Overall survival was significantly longer in the blinatumomab group than in the chemotherapy group. The median overall survival was 7.7 months in the blinatumomab group and 4.0 months in the chemotherapy group (hazard ratio for death with blinatumomab vs. che …
Overall survival was significantly longer in the blinatumomab group than in the chemotherapy group. The median overall survival was 7 …
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS. Litzow MR, et al. N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948. N Engl J Med. 2024. PMID: 39047240 Free PMC article. Clinical Trial.
At a median follow-up of 43 months, an advantage was observed in the blinatumomab group as compared with the chemotherapy-only group with regard to overall survival (at 3 years: 85% vs. 68%; hazard ratio for death, 0.41; 95% confidence interval [CI], 0.23 to 0.73; P = 0.00 …
At a median follow-up of 43 months, an advantage was observed in the blinatumomab group as compared with the chemotherapy-only group …
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Mergen N, Mohammad A, Kormany WN, Eckert C, Möricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A. Locatelli F, et al. JAMA. 2021 Mar 2;325(9):843-854. doi: 10.1001/jama.2021.0987. JAMA. 2021. PMID: 33651091 Free PMC article. Clinical Trial.
IMPORTANCE: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). ...Enrollment was terminated early for benefit of blinatumomab in accordance with a …
IMPORTANCE: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refract …
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, Raetz EA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Pulsipher MA, Hunger SP, Loh ML. Brown PA, et al. JAMA. 2021 Mar 2;325(9):833-842. doi: 10.1001/jama.2021.0669. JAMA. 2021. PMID: 33651090 Free PMC article. Clinical Trial.
Eligible patients included those aged 1 to 30 years with B-ALL first relapse, excluding those with Down syndrome, Philadelphia chromosome-positive ALL, prior hematopoietic stem cell transplant, or prior blinatumomab treatment (n = 669). INTERVENTIONS: All patients received …
Eligible patients included those aged 1 to 30 years with B-ALL first relapse, excluding those with Down syndrome, Philadelphia chromosome-po …
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML. Gupta S, et al. N Engl J Med. 2025 Feb 27;392(9):875-891. doi: 10.1056/NEJMoa2411680. Epub 2024 Dec 7. N Engl J Med. 2025. PMID: 39651791 Free PMC article. Clinical Trial.
Cytokine release syndrome, seizures, and sepsis of grade 3 or higher were rare during blinatumomab cycles, but the overall incidence of nonfatal sepsis and catheter-related infections was significantly higher among patients with an average relapse risk who had been assigne …
Cytokine release syndrome, seizures, and sepsis of grade 3 or higher were rare during blinatumomab cycles, but the overall incidence …
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.
Hogan LE, Brown PA, Ji L, Xu X, Devidas M, Bhatla T, Borowitz MJ, Raetz EA, Carroll A, Heerema NA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Hunger SP, Loh ML. Hogan LE, et al. J Clin Oncol. 2023 Sep 1;41(25):4118-4129. doi: 10.1200/JCO.22.02200. Epub 2023 May 31. J Clin Oncol. 2023. PMID: 37257143 Free PMC article. Clinical Trial.
PURPOSE: Blinatumomab, a bispecific T-cell engager immunotherapy, is efficacious in relapsed/refractory B-cell ALL (B-ALL) and has a favorable toxicity profile. ...For isolated EM (IEM; n = 81) relapses, 4-year DFS/OS were 36.6% 8.2%/76.5% 7.5% for blinatumomab vers …
PURPOSE: Blinatumomab, a bispecific T-cell engager immunotherapy, is efficacious in relapsed/refractory B-cell ALL (B-ALL) and has a …
Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis.
Zhai Y, Hong J, Wang J, Jiang Y, Wu W, Lv Y, Guo J, Tian L, Sun H, Li Y, Li C, Zhan H, Zhao Z. Zhai Y, et al. Expert Rev Hematol. 2024 Jan-Mar;17(1-3):67-76. doi: 10.1080/17474086.2023.2298732. Epub 2024 Jan 4. Expert Rev Hematol. 2024. PMID: 38135295 Review.
RESULTS: The pooled complete remission (CR) rate and minimal residual disease (MRD) negative rate were 48%, 31% for blinatumomab, and 86% and 80% for CAR T-cell therapy. CONCLUSIONS: The CAR T-cell therapy group exhibited a higher likelihood of CR rate than the blinatum …
RESULTS: The pooled complete remission (CR) rate and minimal residual disease (MRD) negative rate were 48%, 31% for blinatumomab, and …
Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis.
Liu H, Xi R, Mao D, Zhao X, Wu T. Liu H, et al. Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):e139-e149. doi: 10.1016/j.clml.2022.12.009. Epub 2022 Dec 17. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36593170 Review.
OBJECTIVE: The aim was to evaluate the efficacy and safety of blinatumomab monotherapy for the treatment of relapsed/refractory acute lymphoblastic leukemia (R/R B-ALL). METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched to collect clinical studies …
OBJECTIVE: The aim was to evaluate the efficacy and safety of blinatumomab monotherapy for the treatment of relapsed/refractory acute …
Efficacy and safety of blinatumomab for the treatment of patients relapsing after allogeneic hematopoietic cell transplantation: a systemic review and meta-analysis.
Guo HP, Liu Y, Kang L, Liu C, Qin WW. Guo HP, et al. Hematology. 2024 Dec;29(1):2422151. doi: 10.1080/16078454.2024.2422151. Epub 2024 Nov 18. Hematology. 2024. PMID: 39556332 Free article. Review.
OBJECTIVE: We aim to evaluate the efficacy and safety of blinatumomab for the treatment of post-transplant relapse patients with acute lymphoblastic leukemia (ALL). METHODS: The search was conducted using several databases including the PubMed, Cochrane Library, Embase, Ch …
OBJECTIVE: We aim to evaluate the efficacy and safety of blinatumomab for the treatment of post-transplant relapse patients with acut …
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia.
Wei AH, Ribera JM, Larson RA, Ritchie D, Ghobadi A, Chen Y, Anderson A, Dos Santos CE, Franklin J, Kantarjian H. Wei AH, et al. Leukemia. 2021 Aug;35(8):2220-2231. doi: 10.1038/s41375-020-01089-x. Epub 2021 Feb 4. Leukemia. 2021. PMID: 33542479 Free PMC article. Clinical Trial.
Patients were randomized 2:1 to receive blinatumomab, a BiTE() therapy, for 4 weeks (9 mug/day cycle 1 week 1, 28 mug/day thereafter) every 6 weeks, or chemotherapy. ...Incorporating baseline biomarkers into future studies may help to identify subgroups most likely to bene …
Patients were randomized 2:1 to receive blinatumomab, a BiTE() therapy, for 4 weeks (9 mug/day cycle 1 week 1, 28 mug/day thereafter) …
21 results

Searches related to "blinatumomab"